ES2541217T3 - Diferenciación de células madre mesenquimales - Google Patents

Diferenciación de células madre mesenquimales Download PDF

Info

Publication number
ES2541217T3
ES2541217T3 ES10800425.0T ES10800425T ES2541217T3 ES 2541217 T3 ES2541217 T3 ES 2541217T3 ES 10800425 T ES10800425 T ES 10800425T ES 2541217 T3 ES2541217 T3 ES 2541217T3
Authority
ES
Spain
Prior art keywords
polypeptide
seq
nos
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10800425.0T
Other languages
English (en)
Spanish (es)
Inventor
Kristen Johnson
Lori Jennings
Peter Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Scripps Research Institute
Original Assignee
Novartis AG
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43450138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2541217(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG, Scripps Research Institute filed Critical Novartis AG
Application granted granted Critical
Publication of ES2541217T3 publication Critical patent/ES2541217T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES10800425.0T 2009-07-14 2010-07-13 Diferenciación de células madre mesenquimales Active ES2541217T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22529309P 2009-07-14 2009-07-14
US225293P 2009-07-14
PCT/US2010/041850 WO2011008773A2 (en) 2009-07-14 2010-07-13 Mesenchymal stem cell differentiation

Publications (1)

Publication Number Publication Date
ES2541217T3 true ES2541217T3 (es) 2015-07-16

Family

ID=43450138

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10800425.0T Active ES2541217T3 (es) 2009-07-14 2010-07-13 Diferenciación de células madre mesenquimales

Country Status (30)

Country Link
US (4) US9139633B2 (show.php)
EP (1) EP2453921B1 (show.php)
JP (1) JP5602850B2 (show.php)
KR (3) KR101590834B1 (show.php)
CN (2) CN105601728B (show.php)
AU (1) AU2010273570B2 (show.php)
BR (1) BR112012000914B8 (show.php)
CA (1) CA2767826C (show.php)
CL (1) CL2012000091A1 (show.php)
CO (1) CO6491059A2 (show.php)
CR (1) CR20120024A (show.php)
CU (1) CU24042B1 (show.php)
EA (1) EA023073B1 (show.php)
EC (1) ECSP12011604A (show.php)
ES (1) ES2541217T3 (show.php)
GT (1) GT201200011A (show.php)
IL (2) IL217383A (show.php)
IN (1) IN2012DN00572A (show.php)
MA (1) MA33423B1 (show.php)
MX (1) MX2012000707A (show.php)
MY (1) MY160951A (show.php)
NZ (1) NZ597306A (show.php)
PE (2) PE20160507A1 (show.php)
PL (1) PL2453921T3 (show.php)
PT (1) PT2453921E (show.php)
SG (1) SG177318A1 (show.php)
TN (1) TN2011000655A1 (show.php)
UA (1) UA104031C2 (show.php)
WO (1) WO2011008773A2 (show.php)
ZA (1) ZA201200078B (show.php)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2453921E (pt) * 2009-07-14 2015-09-25 Novartis Ag Diferenciação de células estaminais mesenquimais
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
JP5969041B2 (ja) 2011-11-08 2016-08-10 エレクトロニクス アンド テレコミュニケーションズ リサーチ インスチチュートＥｌｅｃｔｒｏｎｉｃｓ Ａｎｄ Ｔｅｌｅｃｏｍｍｕｎｉｃａｔｉｏｎｓ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 候補リスト共有方法及びこのような方法を使用する装置
CN104619727B (zh) 2012-06-25 2019-04-05 布里格姆及妇女医院股份有限公司 靶向治疗
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
ES2900815T3 (es) 2013-03-15 2022-03-18 Scripps Research Inst Compuestos y métodos para inducir la condrogénesis
PE20161432A1 (es) 2014-05-13 2017-01-08 Novartis Ag Compuestos y composiciones para inducir condrogenesis
CN104840486A (zh) * 2015-04-30 2015-08-19 北京益诺勤生物技术有限公司 一种组合物及其应用、制剂
CN109069868B (zh) 2016-03-03 2023-06-06 瑞泽恩制药公司 通过施用与angptl3抑制剂组合的pcsk9抑制剂治疗高脂血症患者的方法
JP2019535707A (ja) * 2016-11-14 2019-12-12 ノバルティス アーゲー 軟骨損傷および関節炎の処置のための方法および組成物
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
CN113015735B (zh) 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的5-羟基-7-氧杂双环[2.2.1]庚烷-2-甲酰胺衍生物
CN113015736B (zh) * 2018-12-06 2024-06-21 诺华股份有限公司 用于诱导软骨发生以治疗关节损害的6-羟基-8-氧杂三环[3.2.1.02,4]辛烷-2-甲酰胺衍生物
CN109432128A (zh) * 2018-12-07 2019-03-08 卡替（上海）生物技术股份有限公司 牙髓间充质干细胞在银屑病治疗中的应用
KR102246582B1 (ko) * 2019-04-03 2021-04-30 이화여자대학교 산학협력단 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
WO2000053757A2 (en) 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
WO1999058660A1 (en) * 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
AU3661199A (en) 1998-04-27 1999-11-16 Zymogenetics Inc. Novel polypeptide growth factors and materials and methods for making them
WO1999067382A2 (en) 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
EP1198568B1 (en) * 1999-07-20 2007-07-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20030120056A1 (en) * 2000-10-16 2003-06-26 Audrey Goddard TIE ligand homologues
ATE456655T1 (de) * 2000-10-16 2010-02-15 Genentech Inc Behandlungsverfahren unter verwendung von wisp- polypeptiden
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
KR101012904B1 (ko) * 2001-11-16 2011-02-08 제넨테크, 인크. 안지오포이에틴-유사 단백질 3 ａｎｇｐｔｌ3을 함유하는조성물 및 이를 사용하는 방법
AP2005003246A0 (en) * 2002-09-09 2005-03-31 Nektar Therapeutics Al Corp Water-soluble polymer alkanals
KR100818689B1 (ko) * 2003-03-10 2008-04-02 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 간엽계 간세포의 식별방법
JP3979372B2 (ja) 2003-09-26 2007-09-19 ブラザー工業株式会社 画像処理装置、画像処理方法及び画像処理プログラム
ATE551066T1 (de) * 2004-06-21 2012-04-15 Cleveland Clinic Foundation Ccr-liganden für stammzellen-homing
JP2008532516A (ja) 2005-03-11 2008-08-21 ジェネンテック・インコーポレーテッド 遺伝子破壊、組成物、およびそれに関連する方法
EP1899457B1 (en) 2005-05-24 2012-09-05 Whitehead Institute For Biomedical Research Methods for expansion and analysis of cultured hematopoietic stem cells
US7601501B2 (en) * 2006-08-11 2009-10-13 The Scripps Research Institute Controlling osteogenesis by inhibition of osteogenic suppressors
EP2155862A2 (en) * 2007-05-04 2010-02-24 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
PT2453921E (pt) * 2009-07-14 2015-09-25 Novartis Ag Diferenciação de células estaminais mesenquimais
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage

Also Published As

Publication number Publication date
IN2012DN00572A (show.php) 2015-06-12
IL217383A0 (en) 2012-02-29
CA2767826A1 (en) 2011-01-20
PT2453921E (pt) 2015-09-25
US10555990B2 (en) 2020-02-11
CN102625830A (zh) 2012-08-01
GT201200011A (es) 2013-12-10
CU24042B1 (es) 2014-11-27
JP2012533549A (ja) 2012-12-27
MX2012000707A (es) 2012-03-21
BR112012000914A2 (pt) 2017-08-08
PE20120570A1 (es) 2012-05-19
ECSP12011604A (es) 2012-06-29
EA201200118A1 (ru) 2012-09-28
UA104031C2 (uk) 2013-12-25
US20190000922A1 (en) 2019-01-03
IL217383A (en) 2016-08-31
CR20120024A (es) 2012-06-11
WO2011008773A2 (en) 2011-01-20
KR20180000337A (ko) 2018-01-02
KR20160015403A (ko) 2016-02-12
EP2453921B1 (en) 2015-05-27
IL247310B (en) 2018-04-30
CN102625830B (zh) 2016-03-02
US20160213748A1 (en) 2016-07-28
BR112012000914B8 (pt) 2021-05-25
JP5602850B2 (ja) 2014-10-08
AU2010273570B2 (en) 2014-07-03
BR112012000914B1 (pt) 2021-04-06
US20200108122A1 (en) 2020-04-09
US9139633B2 (en) 2015-09-22
CN105601728A (zh) 2016-05-25
KR20120029472A (ko) 2012-03-26
US11241482B2 (en) 2022-02-08
SG177318A1 (en) 2012-03-29
TN2011000655A1 (en) 2013-05-24
ZA201200078B (en) 2013-01-30
PE20160507A1 (es) 2016-05-20
AU2010273570A1 (en) 2012-02-02
WO2011008773A3 (en) 2011-08-25
MY160951A (en) 2017-03-31
CL2012000091A1 (es) 2012-10-26
BR112012000914A8 (pt) 2017-12-19
PL2453921T3 (pl) 2015-11-30
KR101590834B1 (ko) 2016-02-12
NZ597306A (en) 2014-03-28
EA023073B1 (ru) 2016-04-29
US10064918B2 (en) 2018-09-04
CN105601728B (zh) 2020-01-10
US20120177644A1 (en) 2012-07-12
CA2767826C (en) 2015-11-24
CO6491059A2 (es) 2012-07-31
HK1164169A1 (en) 2012-09-21
EP2453921A4 (en) 2012-12-19
CU20120007A7 (es) 2013-02-26
EP2453921A2 (en) 2012-05-23
MA33423B1 (fr) 2012-07-03

Similar Documents

Publication Publication Date Title
ES2541217T3 (es) Diferenciación de células madre mesenquimales
ES2540858T3 (es) Composición farmacéutica para el tratamiento y/o la prevención de cáncer
ES2606173T3 (es) Composición farmacéutica para el tratamiento y/o la prevención del cáncer
ES2619322T3 (es) Agente inductor de inmunidad
ES2486675T3 (es) Análogo de péptido de oxintomodulina
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2650463T3 (es) Tratamiento de enfermedades inflamatorias con ACE2
ES2692918T3 (es) Métodos y composiciones para producir aldehídos grasos
ES2652643T3 (es) Péptidos terapéuticos y su uso contra la corea de Huntington
ES2666720T3 (es) Composición para prevenir o tratar el cáncer de cuello uterino con un potenciador de la inmunidad contra el virus de papiloma humano
ES2616658T3 (es) Péptidos que mimetizan el factor de crecimiento y sus usos
CL2013003146A1 (es) Formulación estable que comprende anticuerpo anti alfa 4 beta 7 y al menos un aminoacido libre; metodo para preparar la formulación; uso para tratar enfermedad inflamatoria.
PE20171111A1 (es) Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso
PT2121731E (pt) Vacinas peptídicas para cancros que expressam antigénios associados a tumores
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
UY33025A (es) Composicion farmaceutica que comprende un agonista de glp-1 metionina
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
AR082805A1 (es) PEPTIDO O COMPLEJO PEPTIDICO QUE SE UNE A INTEGRINA a2 Y METODOS Y USOS QUE IMPLICAN A LOS MISMOS
EP4276180A3 (en) Clostridium histolyticum enzyme
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
CL2019003410A1 (es) Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407).
CL2017002233A1 (es) Un factor de coagulación (fvii o fviia) modificado con tres péptidos carboxi terminal de gonadotropina coriónica unidos al carboxi terminal de fvii o fviia; polinucleótido que lo codifica; composición farmacéutica que lo comprende; uso de fvii o fviia modificado para el tratamiento de coagulación de la sangre o un trastorno de coagulación; método para extender la vía media biológica de un factor de coagulación; método para producir dicho fvii o fviia.
MX2017008410A (es) Reduccion selectiva de residuos cisteina en anticuerpos il-17.
CL2012001609A1 (es) Polipéptido de fusión contra tumor inducido por virus epstein-barr (eb) formado por la unión de polipéptido mutante de colicina ia, el cual pude formar canales iónicos, y que tiene las mutaciones g11a, h22g, a26g, v31l y h40d, con un anticuerpo anti-virus eb o un polipéptido mimético de anticuerpo anti-virus eb; gen codificante de dicho polipéptido; plásmido de recombinación que comprende dicho gen; método de preparación de dicho polipéptido; uso médico de dicho polipéptido; polipéptido mutante de colicina ia con sec id n°24 (con mutaciones mutaciones g11a, h22g, a26g, v31l y h40d); gen codificante de dicho polipéptido; uso médico de dicho gen.
AR102410A1 (es) Polipéptidos que tienen actividad xilanasa con una tasa de conversión alta de polisacáridos que contienen xilosa